Avatrial and OIA Announce Partnership: Building Together the Future of Immune Health and Precision Oncology for Drug Discovery
We are pleased to announce that OIA and Avatrial have signed a Memorandum of Understanding to establish a strategic collaboration that brings together two complementary visions: advancing oncology discovery and pioneering AI-enabled immune diagnostics.
Prof Kourosh Saeb-Parsy, founder of Avatrial and Chief Medical Officer of OIA, and Dr Hector Zenil, founder of Oxford Immune Algorithmics (OIA) and AI advisor of Avatrial, have authored over 300 peer-reviewed papers published in the world’s highest-impact journals across their fields of research, covering systems immunology and AI applied to cell and molecular biology. Both companies are deep tech ventures, the result of the best research from the most prestigious universities in the United Kingdom.
A shared vision
Avatrial is creating one of the world’s most comprehensive, multi-dimensional health and disease highly curated multi-omic datasets with the aim of transforming our understanding of how cancer begins, improving diagnosis, and accelerating the discovery of novel therapeutic targets. By combining samples from patients and healthy volunteers with deep molecular, cellular and clinical data, Avatrial is reshaping the foundations of translational oncology.
With unprecedented granted access to NHS data, Oxford Immune Algorithmics is pioneering and validating AI-enabled diagnostic tools for remote digital testing, making advanced health and immune system monitoring intelligent and accessible outside traditional hospital and lab settings. Through its Algocyte platform and distributed testing infrastructure, OIA enables individuals and clinicians to access actionable AGI-driven and personalised insights into their immune health while allowing researchers and clinicians to track changes and make predictions for early prediction and disease management.
The partnership
This collaboration creates a unique synergy between cutting-edge biomedical data and AI-driven immune system analytics. Together, Avatrial and OIA will:
Enable volunteers to contribute to cancer research and drug discovery under Avatrial’s unprecedented ethical approvals
Integrate datasets to support new discoveries in early disease detection and personalised immune health monitoring
Combine multi-omics data with AI-driven blood diagnostics, delivering what will become the most comprehensive personalised testing and multi-modal research platform approach to date
Build a scalable, patient-centred ecosystem that reduces costs whilst maximising engagement and scientific value
The partnership will also support the integration of Avatrial’s research protocols within OIA’s Algocyte platform, streamlining user onboarding, informed consent, personalised health questionnaires for differential diagnosis hypotheses in a seamless and secure digital environment.
Why it matters
By uniting oncology-focused biomedical research for drug discovery with AI-powered immune diagnostics, this partnership lays the groundwork for a new paradigm in predictive and precision medicine. The potential impact is significant, from improving cancer detection and treatment personalisation to enabling broader access to proactive immune health monitoring.
Looking ahead
This agreement marks the beginning of a long-term strategic relationship between Avatrial and OIA. The two organisations will continue working in good faith towards expanding opportunities where their datasets and technologies can be combined for transformative healthcare innovation.
Together, we are building a new model for data-driven, patient-centred healthcare innovation.
#HealthcareInnovation #AI #Oncology #ImmuneHealth #PrecisionMedicine #PredictiveMedicine #AI4Science #PersonalisedMultiOmics